172 related articles for article (PubMed ID: 36339927)
1. Radiotherapy may augment response to immunotherapy in metastatic uveal melanoma patients.
Grynberg S; Stoff R; Asher N; Shapira-Frommer R; Schachter J; Haisraely O; Lawrence Y; Ben-Betzalel G
Ther Adv Med Oncol; 2022; 14():17588359221131521. PubMed ID: 36339927
[TBL] [Abstract][Full Text] [Related]
2. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.
Bol KF; Ellebaek E; Hoejberg L; Bagger MM; Larsen MS; Klausen TW; Køhler UH; Schmidt H; Bastholt L; Kiilgaard JF; Donia M; Svane IM
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623302
[TBL] [Abstract][Full Text] [Related]
3. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and tolerability.
Backlund E; Grozman V; Egyhazi Brage S; Lewensohn R; Lindberg K; Helgadottir H
Acta Oncol; 2023 Dec; 62(12):1921-1930. PubMed ID: 37966921
[TBL] [Abstract][Full Text] [Related]
6. Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.
Kelly D; Rose AAN; Muniz TP; Hogg D; Butler MO; Saibil SD; King I; Kamil ZS; Ghazarian D; Ross K; Iafolla M; Araujo DV; Waldron J; Laperriere N; Krema H; Spreafico A
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298857
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N
ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104
[TBL] [Abstract][Full Text] [Related]
8. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.
Tong TML; van der Kooij MK; Speetjens FM; van Erkel AR; van der Meer RW; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Burgmans MC; Kapiteijn E
Trials; 2022 Feb; 23(1):137. PubMed ID: 35152908
[TBL] [Abstract][Full Text] [Related]
9. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy.
Orloff M
Ocul Oncol Pathol; 2021 Jun; 7(3):168-176. PubMed ID: 34307327
[TBL] [Abstract][Full Text] [Related]
11. Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
Blomen CL; Kött J; Hartung TI; Torster LK; Gebhardt C
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34945010
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma.
Mignard C; Deschamps Huvier A; Gillibert A; Duval Modeste AB; Dutriaux C; Khammari A; Avril MF; Kramkimel N; Mortier L; Marcant P; Lesimple T; Gaudy-Marqueste C; Lesage C; Machet L; Aubin F; Meyer N; Beneton N; Jeudy G; Montaudié H; Arnault JP; Visseaux L; Trabelsi S; Amini-Adle M; Maubec E; Le Corre Y; Lipsker D; Wierzbicka-Hainaut E; Litrowski N; Stefan A; Brunet-Possenti F; Leccia MT; Joly P
J Oncol; 2018; 2018():1908065. PubMed ID: 30631354
[TBL] [Abstract][Full Text] [Related]
13. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
[TBL] [Abstract][Full Text] [Related]
14. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
Jindal V
Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567
[TBL] [Abstract][Full Text] [Related]
15. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract][Full Text] [Related]
16. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254
[TBL] [Abstract][Full Text] [Related]
18. Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study.
Vanaken L; Woei-A-Jin FJSH; Van Ginderdeuren R; Deroose CM; Laenen A; Missotten G; Thal DR; Bechter O; Schöffski P; Clement P
Acta Oncol; 2023 May; 62(5):480-487. PubMed ID: 37200223
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and treatment outcomes of progressive uveal melanoma.
Rancelyte M; Pamedys J; Grigiene R; Brasiuniene B
Arch Clin Cases; 2023; 10(2):102-106. PubMed ID: 37359088
[TBL] [Abstract][Full Text] [Related]
20. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.
Qin Y; Petaccia de Macedo M; Reuben A; Forget MA; Haymaker C; Bernatchez C; Spencer CN; Gopalakrishnan V; Reddy S; Cooper ZA; Fulbright OJ; Ramachandran R; Wahl A; Flores E; Thorsen ST; Tavera RJ; Conrad C; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Amaria RN; Hwu P; Wargo JA; Lazar AJ; Patel SP
Oncoimmunology; 2017; 6(6):e1321187. PubMed ID: 28680759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
